ST2 and Galectin-3 Biomarker Panel for Cardiovascular Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting adverse clinical outcomes in subjects with cardiovascular diseases, particularly in determining the risk of adverse clinical outcomes and selecting appropriate therapeutic treatments.
Innovation Solution
Determining the levels of galectin-3 and ST2 in biological samples to assess the risk of adverse clinical outcomes, decide on treatment initiation or continuation, and select subjects for clinical studies or therapeutic treatments, using these biomarkers to guide decisions on patient management and treatment selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used for predicting adverse clinical outcomes, then existing diagnostic approaches are maintained, but prediction accuracy and reliability are insufficient
Solution Approach 1:
The patent combines multiple biomarkers (galectin-3, ST2, and other cardiac markers) into an integrated diagnostic approach. This merging of multiple detection targets allows for more reliable prediction of adverse clinical outcomes by considering multiple pathological aspects simultaneously, thereby improving both reliability and measurement precision.
Solution Approach 2:
The patent employs a composite biomarker panel rather than relying on a single marker. This composite approach integrates galectin-3, ST2, and other cardiac biomarkers to create a more comprehensive and accurate prediction system, enhancing the reliability of adverse outcome prediction through multi-parameter assessment.
2Reliability
If multiple biomarkers are measured to improve prediction accuracy, then reliability increases, but test complexity and cost increase
Solution Approach 1:
The patent describes a multi-functional diagnostic system that can simultaneously detect multiple biomarkers (galectin-3, ST2, and other cardiac markers) using a single integrated approach. This universal testing system performs multiple diagnostic functions in one assay, reducing overall system complexity while maintaining high reliability through comprehensive biomarker assessment.
Solution Approach 2:
The patent segments the diagnostic process into distinct biomarker detection components (galectin-3 detection, ST2 detection, and other cardiac marker detection) that can be performed systematically. This segmentation allows for organized, modular testing that manages complexity through structured multi-parameter assessment while maintaining reliable risk prediction.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that include an antibody that specifically binds to ST2 and an antibody that specifically binds to galectin-3.